Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patriarca

Showing results (901-910 of 1,012) with videos related to

Pageof 102
Sort By:
Bone Marrow Transplantation|June 24, 2026
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remissionDaniele Avenoso, Vera Radici, Alessandro Leoni, et al.
Annals of Hematology|July 15, 2026
Prophylaxis and management of thromboembolism in pnh patients: an italian surveyAnna Paola Iori, Rosario Notaro, Martina Salvatori, et al.
Leukemia|May 23, 2021
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMTNicolaus Kröger, Giulia Sbianchi, Tiarlan Sirait, et al.
Transplantation and Cellular Therapy|November 6, 2024
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic TransplantationChiara Nozzoli, Martina Pucillo, Luisa Giaccone, et al.
Haematologica|May 10, 2007
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regionsAndrés J M Ferreri, Giuseppina P Dognini, Elías Campo, et al.
The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2013
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor RegistryRoberto Passera, Simona Pollichieni, Lucia Brunello, et al.
Leukemia|December 24, 2016
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysisF Gay, S Oliva, M T Petrucci, et al.
Vaccines|May 7, 2025
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 StudiesAnna Sicuranza, Massimo Breccia, Francesco Iuliano, et al.
Pageof 102

Showing results (901-910 of 1,012) with videos related to

Sort By:
Pageof 102
Bone Marrow Transplantation|June 24, 2026
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remissionDaniele Avenoso, Vera Radici, Alessandro Leoni, et al.
Annals of Hematology|July 15, 2026
Prophylaxis and management of thromboembolism in pnh patients: an italian surveyAnna Paola Iori, Rosario Notaro, Martina Salvatori, et al.
Leukemia|May 23, 2021
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMTNicolaus Kröger, Giulia Sbianchi, Tiarlan Sirait, et al.
Transplantation and Cellular Therapy|November 6, 2024
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic TransplantationChiara Nozzoli, Martina Pucillo, Luisa Giaccone, et al.
Haematologica|May 10, 2007
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regionsAndrés J M Ferreri, Giuseppina P Dognini, Elías Campo, et al.
The New England Journal of Medicine|September 4, 2014
Autologous transplantation and maintenance therapy in multiple myelomaAntonio Palumbo, Federica Cavallo, Francesca Gay, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2013
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor RegistryRoberto Passera, Simona Pollichieni, Lucia Brunello, et al.
Leukemia|December 24, 2016
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysisF Gay, S Oliva, M T Petrucci, et al.
Vaccines|May 7, 2025
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 StudiesAnna Sicuranza, Massimo Breccia, Francesco Iuliano, et al.
Pageof 102